Vaccination May Speed Up Influenza Evolution, Model Warns

Every winter, influenza returns to haunt human populations, and every winter it arrives slightly changed. The reason is that respiratory viruses do not simply persist in a population despite our immune memories; in a very real sense, they persist because of the evolutionary pressure those memories impose. Antibodies generated by past infections and vaccinations continually push the virus to reshape the outer proteins that our immune system recognizes, and the virus responds by accumulating mutations that blunt that recognition. A new theoretical study published in PLOS Pathogens by Igor M. Rouzine couples the mathematics of epidemic spread to the mathematics of multilocus viral evolution to ask a question with immediate practical consequences: under what conditions does vaccination actually help a population win the race against an evolving influenza virus, and under what conditions might it inadvertently accelerate the opponent?

The central insight of the work is that vaccination and natural infection are not independent processes acting on a static target. When a large fraction of a population carries antibodies against the currently dominant viral variant, the virus experiences strong selection favoring any mutant that can evade those antibodies. Vaccination, by expanding the pool of immune individuals, increases this selective pressure. In the language of evolutionary biology, vaccination raises the herd immunity threshold that the virus must climb, and in doing so it can speed up the very evolutionary race it is meant to end. The model shows that this acceleration is not a marginal effect; depending on parameter choices informed by real influenza data, vaccination can measurably shorten the time it takes for an escape variant to emerge and spread, and in some regimes it may even increase the incidence of infection rather than reduce it.

To reach this conclusion, Rouzine built a framework that links two traditionally separate layers of description. The first layer is an epidemiological model of a population infected with a continuously evolving virus, tracking how susceptible, infected, and immune individuals change over time as the virus drifts antigenically. The second layer is a model of evolution at multiple genetic loci, capturing the fact that antibody escape in influenza typically requires not a single mutation but a coordinated combination of changes across several sites in the viral genome. The two layers feed into each other: the epidemiological state of the population determines how strongly each escape mutation is selected, while the evolving viral variant determines who is susceptible and who is protected. This coupling is what allows the model to ask about vaccination in a dynamically meaningful way, rather than treating the virus as a fixed adversary.

The parameters of the coupled model were chosen to reflect empirical data on influenza virus, including the characteristic rates of mutation, the strength of antibody selection, and the epidemiological turnover of the virus in human populations. This grounding matters because the qualitative behavior of such models can change dramatically with parameter values. A model calibrated to arbitrary numbers might predict almost anything; a model anchored to measured influenza biology is constrained to explore the regime in which real vaccine campaigns actually operate. Within that regime, the study examined how the outcome of a vaccination program depends on the properties of the antibodies that the vaccine elicits and on the timing and positioning of the vaccine strain relative to the circulating virus.

A key structural distinction in the analysis concerns whether the protective effects of consecutive vaccinations overlap or do not overlap. In the overlapping case, antibodies elicited by successive vaccine formulations recognize overlapping sets of viral variants, so that a person vaccinated in consecutive seasons accumulates a broader shield of immunity. In the non-overlapping case, each vaccination generates antibodies against a distinct set of variants, and the protection from one campaign does not reinforce the protection from the next. The model treats these scenarios separately because they lead to different evolutionary dynamics. When effects overlap, the immune pressure on the virus is more coherent and sustained; when they do not, the virus faces a more fragmented landscape of selection, which changes both the pace of escape and the composition of escape mutations that succeed.

The most striking predictions concern two scenarios in which vaccination avoids backfiring. The first is that antibodies elicited by the vaccine are more broadly neutralizing than the antibodies generated by natural infection. If the vaccine induces a wider repertoire of recognition, targeting conserved features or a broader panel of antigenic variants, then the immune pressure it adds is not so easily escaped by a small number of mutations, and the evolutionary race slows in favor of the population. The second scenario is that the vaccine vector lies slightly ahead of the dominant viral variant along the evolutionary trajectory of the virus. In other words, if the vaccine anticipates the next step of viral evolution rather than chasing the variant that is already circulating, vaccination pre-arms the population against the variant that selection is about to favor, and the anticipated escape loses its advantage.

Both scenarios are demanding, and the model is candid about what happens when neither is met. A vaccine that elicits antibodies no broader than those from natural infection, and that targets a strain already dominant or already receding, adds immune pressure against variants the virus is abandoning while leaving the emerging escape path open. The result can be a net acceleration of viral evolution, with the ironic possibility that vaccination increases infection incidence by hastening the arrival of variants that evade existing immunity in the population. This does not mean that vaccination is futile; it means that the design and timing of vaccination matter in ways that a static view of immunity cannot capture. The value of a vaccine against a rapidly evolving virus depends on where it sits in the evolutionary race, not merely on how many people receive it.

These findings carry a constructive message for vaccine development. The study suggests that the probabilistic prognosis of virus evolution, meaning the forecasting of which variants are likely to arise and spread under current immune conditions, represents a promising strategy for improving vaccines, complementing the ongoing search for broadly neutralizing vaccines. Broadly neutralizing antibodies remain the gold standard, because they collapse the evolutionary escape routes available to the virus. But developing such vaccines for influenza has proved difficult, and the model indicates that a second, complementary path exists: using evolutionary models to place conventional vaccine strains slightly ahead of the dominant circulating variant, so that the immunity induced by vaccination intercepts the virus where it is going rather than where it has been. In this framing, vaccine selection becomes a forecasting problem, and the quality of the forecast directly determines whether vaccination helps or hinders the population.

The work also illustrates a broader principle in the study of rapidly evolving pathogens: epidemiology and evolution cannot be fully understood in isolation. The composition of the immune population shapes which mutations are beneficial to the virus, and the mutations that succeed reshape the epidemiology of the following season. Models that couple these processes, as the present study does, can capture feedback loops that simpler approaches miss, including the counterintuitive result that increasing immunity in a population can, under some conditions, increase the speed at which immune escape occurs. For influenza, where antigenic drift forces annual reformulation of vaccines and where prediction of the coming season’s strains remains an imperfect science, such coupled models offer a quantitative language for discussing why some vaccine campaigns perform better than others.

As with any theoretical study, the predictions rest on model assumptions and on the parameter values drawn from influenza data, and translating them into practice will require empirical validation and careful integration with surveillance systems that track viral evolution in near real time. Nevertheless, the conclusions sharpen the agenda for the field. Vaccination against a rapidly evolving respiratory virus is not a static intervention but a move in an ongoing evolutionary game, and the model identifies the conditions under which that move wins: either antibodies broader than nature’s own, or a vaccine strain positioned just ahead of the virus on its evolutionary path. Failing both, the race continues, and the virus may run faster for having been pushed. The study thus reframes vaccine improvement as a problem in evolutionary forecasting, one in which predicting the probabilistic future of the virus becomes as important as measuring its present.

Subject of Research: Modeling how vaccination influences the evolutionary race between influenza virus antigenic escape and collective immunity

Article Title: Vaccination accelerates the race of influenza virus against collective immunity

Article References: Rouzine, I. M. (2026). Vaccination accelerates the race of influenza virus against collective immunity. PLOS Pathogens, 22(10), e1014311. https://doi.org/10.1371/journal.ppat.1014311

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014311

Keywords: influenza, vaccination, viral evolution, antigenic drift, herd immunity, antibody escape, epidemiological model, multilocus evolution, broadly neutralizing antibodies, vaccine design, PLOS Pathogens, evolutionary forecasting